Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen

• FDA approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) for adult patients with muscle-invasive bladder cancer.
• The regimen is cleared for both neoadjuvant and adjuvant use, regardless of cisplatin eligibility.
• This is the first platinum-free treatment option for this indication, following results from the Phase 3 EV-304 trial.

For investors tracking Pfizer (NYSE:PFE), this approval adds a fresh catalyst to an oncology portfolio that remains a core focus for the company. The stock closed at $24.17, with the share price down 5.6% over the past 30 days and down 4.0% year to date, while the 1 year return is up 0.8% and the 3 year and 5 year returns are down 19.8% and 22.6%, respectively. In that context, a new FDA approval in a defined patient population provides another concrete data point when assessing how Pfizer is executing on its pipeline.

For readers, the main question now is how this expanded indication for PADCEV plus Keytruda might influence Pfizer’s oncology mix and future trial priorities. As more data emerge from real world use and any follow-on studies, the market will gain a clearer view of how this non-platinum regimen fits into treatment practice and how meaningful it becomes within Pfizer’s broader revenue base.

Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.

We’ve flagged 4 risks for Pfizer. See which could impact your investment.

Quick Assessment

• ✅ Price vs Analyst Target: Pfizer trades at US$24.17 versus an analyst consensus of about US$28.98, roughly 20% below the target.
• ✅ Simply Wall St Valuation: Shares are flagged as trading about 62.3% below one fair value estimate, suggesting a sizeable valuation gap.
• ❌ Recent Momentum: The stock has fallen 5.6% over the past 30 days, even as this PADCEV plus Keytruda approval comes through.

There’s only one way to know the right time to buy, sell or hold Pfizer. Head to Simply Wall St’s company report for the latest analysis of Pfizer’s Fair Value.

Key Considerations

• 📊 The first platinum free regimen approval strengthens Pfizer’s oncology footprint and adds another approved indication tied to its partnership drugs.
• 📊 Watch uptake in muscle invasive bladder cancer, any label expansions, and how oncology contributes relative to Pfizer’s US$63.3b in revenue.
• ⚠️ Major flagged risks include debt coverage, dividend coverage at a 7.12% yield, and forecasts that point to earnings declines over the next three years.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Pfizer analysis. Alternatively, you can check out the community page for Pfizer to see how other investors believe this latest news will impact the company’s narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com